Cyclodextrin/dendrimer conjugates as DNA and oligonucleotide carriers

Current Topics in Medicinal Chemistry

Volumn 14, Issue 4, 2014, Pages 465-477

  Arima, Hidetoshi ^a   Motoyama, Keiichi ^a   Higashi, Taishi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Cyclodextrin; Folic acid; Gene; Oligonucleotide; Polyamidoamine dendrimer; Polypseudorotaxane; Sugars

Indexed keywords

CYCLODEXTRIN; DENDRIMER; DRUG CARRIER; FOLIC ACID; FUCOSE; GALACTOSE; LACTOSE; MACROGOL; MANNOSE; OLIGONUCLEOTIDE; PLASMID DNA; ROTAXANE; SMALL INTERFERING RNA; VIRUS VECTOR;

CHEMICAL MODIFICATION; CONJUGATE; CYTOTOXICITY; ENDOCYTOSIS; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; NONHUMAN; OLIGONUCLEOTIDE PROBE; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW;

ALPHA-CYCLODEXTRINS; DENDRIMERS; DNA; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; HUMANS;

EID: 84894040297     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026613666131219123610     Document Type: Review

References (117)

1. Pfeifer, A.; Verma, I.M. Gene therapy: Promises and problems. Annu. Rev. Genom. Hum. G., 2001, 2, 177-211.
2. Lowenstein, P. R. Clinical trials in gene therapy: Ethics of informed consent and the future of experimental medicine. Curr. Opin. Mol. Ther., 2008, 10 (5), 428-430.
3. Fischer, A.; Cavazzana-Calvo, M. Gene therapy of inherited diseases. The Lancet, 2008, 371 (9629), 2044-2047.
4. Räty, J.K.; Lesch, H.P.; Wirth, T.; Ylä-Herttuala, S. Improving safety of gene therapy. Curr. Drug Saf., 2008, 3 (1), 46-53.
5. Wang, J.; Lu, Z.; Wientjes, M.G.; Au, J.L.S. Delivery of siRNA therapeutics: Barriers and carriers. AAPS J., 2010, 12 (4), 492-503.
6. Rao, D.D.; Vorhies, J.S.; Senzer, N.; Nemunaitis, J. siRNA vs. shRNA: Similarities and differences. Adv. Drug Del. Rev., 2009, 61 (9), 746-759.
7. Blau, H.M.; Springer, M.L. Gene therapy - A novel form of drug delivery. N. Engl. J. Med., 1995, 333 (18), 1204-1207.
8. Afione, S.A.; Conrad, C.K.; Flotte, T.R. Gene therapy vectors as drug delivery systems. Clin. Pharmacokinet., 1995, 28 (3), 181-189.
9. Grimm, D. Small silencing RNAs: State-of-the-art. Adv. Drug Del. Rev., 2009, 61 (9), 672-703.
10. Takeda, K. Delivery of magic bullets: On the still rocky road to gene therapy. Br. J. Pharmacol., 2009, 157 (2), 151-152.
11. Li, S.D.; Huang, L. Gene therapy progress and prospects: Non-viral gene therapy by systemic delivery. Gene Ther., 2006, 13 (18), 1313-1319.
12. Akhtar, S. Non-viral cancer gene therapy: Beyond delivery. Gene Ther., 2006, 13 (9), 739-740.
13. Rettig, G.R.; Rice, K.G. Non-viral gene delivery: From the needle to the nucleus. Expert Opin. Biol. Th., 2007, 7 (6), 799-808.
14. Cristiano, R.J.; Xu, B.; Nguyen, D.; Schumacher, G.; Kataoka, M.; Spitz, F.R.; Roth, J.A. Viral and nonviral gene delivery vectors for cancer gene therapy. Cancer Detect. Prev., 1998, 22 (5), 445-454.
15. Ma, H.; Diamond, S.L. Nonviral gene therapy and its delivery systems. Curr. Pharm. Biotechnol., 2001, 2 (1), 1-17.
16. Smaglik, P. Tighter watch urged on adenoviral vectors. Nature, 1999, 402 (6763), 707.
17. Yi, Y.; Hahm, S.H.; Lee, K.H. Retroviral gene therapy: Safety issues and possible solutions. Curr. Gene Ther., 2005, 5 (1), 25-35.
18. Thomas, M.; Klibanov, A.M. Non-viral gene therapy: Polycation-mediated DNA delivery. Appl. Microbiol. Biotechnol., 2003, 62 (1), 27-34.
19. Eliyahu, H.; Barenholz, Y.; Domb, A.J. Polymers for DNA delivery. Molecules, 2005, 10 (1), 34-64.
20. Park, J.S.; Akiyama, Y.; Yamasaki, Y.; Kataoka, K. Preparation and characterization of polyion complex micelles with a novel thermosensitive poly(2-isopropyl-2-oxazoline) shell via the complexation of oppositely charged block ionomers. Langmuir, 2007, 23 (1) 138-146.
21. Akagi, D.; Oba, M.; Koyama, H.; Nishiyama, N.; Fukushima, S.; Miyata, T.; Nagawa, H.; Kataoka, K. Biocompatible micellar nanovectors achieve efficient gene transfer to vascular lesions without cytotoxicity and thrombus formation. Gene Ther., 2007, 14 (13), 1029-1038.
22. Gao, K.; Huang, L. Nonviral methods for siRNA delivery. Mol. Pharm., 2009, 6 (3), 651-658.
23. Reischl, D.; Zimmer, A. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine, 2009, 5 (1), 8-20.
24. Tomalia, D.A. Dendrimer research [3]. Science, 1991, 252 (5010), 1231.
25. Tomalia, D.A.; Baker, H.; Dewald, J.; Hall, M.; Kallos, G.; Martin, S.; Roeck, J.; Ryder, J.; Smith, P. A New class of polymers: Starburst-dendritic macromolecules. Polym. J., 1985, 17 (1), 117-132.
26. Mintzer, M.A.; Grinstaff, M.W. Biomedical applications of dendrimers: a tutorial. Chem. Soc. Rev., 2011, 40 (1), 173-190.
27. Kukowska-Latallo, J.F.; Bielinska, A.U.; Johnson, J.; Spindle, R.; Tomalia, D.A.; Baker Jr, J.R. Efficient transfer of genetic material into mammalian cells using starburst polyamidoamine dendrimers. Proc. Natl. Acad. Sci. U. S. A., 1996, 93 (10), 4897-4902.
28. Haensler, J.; Szoka Jr, F.C. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug. Chem., 1993, 4 (5), 372-379.
29. Saenger, W. Stereochemistry of circularly closed oligosaccharides: cyclodextrin structure and function. Biochem. Soc. Trans., 1983, 11(Pt 2), 136-139.
30. Szejtli, J. Medicinal applications of cyclodextrins. Med. Res. Rev., 1994, 14 (3), 353-386.
31. Uekama, K.; Hirayama, F.; Irie, T. Cyclodextrin drug carrier systems. Chem. Rev., 1998, 98 (5), 2045-2076.
32. Ilangumaran, S.; Hoessli, D.C. Effects of cholesterol depletion by cyclodextrin on the sphingolipid microdomains of the plasma membrane. Biochem. J., 1998, 335 (Part 2), 433-440.
33. Rodal, S.K.; Skretting, G.; Garred, O.; Vilhardt, F.; van Deurs, B.; Sandvig, K. Extraction of cholesterol with methyl-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles. Mol. Biol. Cell, 1999, 10 (4), 961-974.
34. Yang, C.; Li, H.; Wang, X.; Li, J. Cationic supramolecules consisting of oligoethyleniminegrafted -cyclodextrins threaded on poly(ethylene oxide) for gene delivery. J. Biomed. Mater. Res. A., 2009, 89, 13-23.
35. Yang, C.; Wang, X.; Li, H.; Goh, S.H.; Li, J. Synthesis and characterization of polyrotaxanes consisting of cationic -cyclodextrins threaded on poly[(ethylene oxide)-ran-(propylene oxide)] as gene carriers. Biomacromolecules, 2007, 8 (11), 3365-3374.
36. Zhang, W.; Chen, Z.; Song, X.; Si, J.; Tang, G. Low generation polypropylenimine dendrimer graft -cyclodextrin: An efficient vector for gene delivery system. Technol. Cancer Res. Treat., 2008, 7 (2), 103-108.
37. Huang, H.; Tang, G.; Wang, Q.; Li, D.; Shen, F.; Zhou, J.; Yu, H. Two novel non-viral gene delivery vectors: Low molecular weight polyethylenimine cross-linked by (2-hydroxypropyl)-cyclodextrin or (2-hydroxypropyl)-cyclodextrin. Chem. Commun., 2006, 14 (22), 2382-2384.
38. Tang, G.P.; Guo, H.Y.; Alexis, F.; Wang, X.; Zeng, S.; Lim, T. M.; Ding, J.; Yang, Y.Y.; Wang, S. Low molecular weight polyethylenimines linked by -cyclodextrin for gene transfer into the nervous system. J. Gene Med., 2006, 8 (6), 736-744.
39. Yamashita, A.; Choi, H.S.; Ooya, T.; Yui, N.; Akita, H.; Kogure, K.; Harashima, H. Improved cell viability of linear polyethylenimine through g-cyclodextrin inclusion for effective gene delivery. ChemBioChem, 2006, 7 (2), 297-302.
40. Ooya, T.; Choi, H.S.; Yamashita, A.; Yui, N.; Sugaya, Y.; Kano, A.; Maruyama, A.; Akita, H.; Ito, R.; Kogure, K.; Harashima, H. Biocleavable polyrotaxane-plasmid DNA polyplex for enhanced gene delivery. J. Am. Chem. Soc., 2006, 128 (12), 3852-3853.
41. Yamada, Y.; Nomura, T.; Harashima, H.; Yamashita, A.; Katoono, R.; Yui, N. Intranuclear DNA release is a determinant of transfection activity for a non-viral vector: biocleavable polyrotaxane as a supramolecularly dissociative condenser for efficient intranuclear DNA release. Biol. Pharm. Bull., 2010, 33 (7), 1218-1222.
42. Yamada, Y.; Nomura, T.; Harashima, H.; Yamashita, A.; Yui, N. Post-nuclear gene delivery events for transgene expression by biocleavable polyrotaxanes. Biomaterials, 2012, 33 (15), 3952-3958.
43. Teijeiro-Osorio, D.; Remuñán-López, C.; Alonso, M.J. Chitosan/cyclodextrin nanoparticles can efficiently transfect the airway epithelium in vitro. Eur. J. Pharm. Biopharm., 2009, 71 (2), 257-263.
44. Zhou, Y.; Wang, H.; Wang, C.; Li, Y.; Lu, W.; Chen, S.; Luo, J.; Jiang, Y.; Chen, J. Receptor-mediated, tumor-targeted gene delivery using folate-terminated polyrotaxanes. Mol. Pharm., 2012, 9 (5), 1067-1076.
45. Hu, Y.; Tang, G.; Liu, J.; Cheng, W.; Yue, Y.; Li, J.; Zhang, P. FGF receptor-mediated gene delivery using ligands coupled to PEI-CyD. J. Biomed. Biotechnol., 2012, 2012, 989235.
46. Li, Z.; Yin, H.; Zhang, Z.; Liu, K.L.; Li, J. Supramolecular anchoring of DNA polyplexes in cyclodextrin-based polypseudorotaxane hydrogels for sustained gene delivery. Biomacromolecules, 2012, 13 (10), 3162-3172.
47. Bienvenu, C.; Martinez, A.; Jimenez Blanco, J.L.; Di Giorgio, C.; Vierling, P.; Ortiz Mellet, C.; Defaye, J.; Garcia Fernandez, J.M. Polycationic amphiphilic cyclodextrins as gene vectors: effect of the macrocyclic ring size on the DNA complexing and delivery properties. Org. Biomol. Chem., 2012, 10 (29), 5570-5581.
48. Diaz-Moscoso, A.; Guilloteau, N.; Bienvenu, C.; Mendez-Ardoy, A.; Blanco, J.L.; Benito, J.M.; Le Gourrierec, L.; Di Giorgio, C.; Vierling, P.; Defaye, J.; Mellet, C.O.; Fernandez, J.M. Mannosyl-coated nanocomplexes from amphiphilic cyclodextrins and pDNA for site-specific gene delivery. Biomaterials, 2011, 32 (29), 7263-7273.
49. Diaz-Moscoso, A.; Le Gourrierec, L.; Gomez-Garcia, M.; Benito, J.M.; Balbuena, P.; Ortega-Caballero, F.; Guilloteau, N.; Di Giorgio, C.; Vierling, P.; Defaye, J.; Ortiz Mellet, C.; Garcia Fernandez, J.M. Polycationic amphiphilic cyclodextrins for gene delivery: synthesis and effect of structural modifications on plasmid DNA complex stability, cytotoxicity, and gene expression. Chemistry, 2009, 15 (46), 12871-12888.
50. Diaz-Moscoso, A.; Vercauteren, D.; Rejman, J.; Benito, J.M.; Ortiz Mellet, C.; De Smedt, S.C.; Fernandez, J.M. Insights in cellular uptake mechanisms of pDNA-polycationic amphiphilic cyclodextrin nanoparticles (CDplexes). J. Control. Release, 2010, 143 (3), 318-325.
51. Mendez-Ardoy, A.; Guilloteau, N.; Di Giorgio, C.; Vierling, P.; Santoyo-Gonzalez, F.; Ortiz Mellet, C.; Garcia Fernandez, J.M. Cyclodextrin-based polycationic amphiphilic click clusters: effect of structural modifications in their DNA complexing and delivery properties. J. Org. Chem., 2011, 76 (15), 5882-5894.
52. Mendez-Ardoy, A.; Urbiola, K.; Aranda, C.; Ortiz-Mellet, C.; Garcia-Fernandez, J.M.; de Ilarduya, C.T. Polycationic amphiphilic cyclodextrin-based nanoparticles for therapeutic gene delivery. Nanomedicine, 2011, 6 (10), 1697-1707.
53. Symens, N.; Mendez-Ardoy, A.; Diaz-Moscoso, A.; Sanchez-Fernandez, E.; Remaut, K.; Demeester, J.; Fernandez, J.M.; De Smedt, S.C.; Rejman, J. Efficient transfection of hepatocytes mediated by mRNA complexed to galactosylated cyclodextrins. Bioconjug. Chem., 2012, 23 (6), 1276-1289.
54. Godinho, B.M.; Ogier, J.R.; Darcy, R.; O'Driscoll, C.M.; Cryan, J.F. Self-assembling modified -cyclodextrin nanoparticles as neuronal siRNA delivery vectors: Focus on huntington's disease. Mol. Pharm., 2013, 10 (2), 640-649.
55. Ping, Y.; Liu, C.; Zhang, Z.; Liu, K.L.; Chen, J.; Li, J. Chitosangraft-(PEI-cyclodextrin) copolymers and their supramolecular PEGylation for DNA and siRNA delivery. Biomaterials, 2011, 32 (32), 8328-8341.
56. Bellocq, N.C.; Pun, S.H.; Jensen, G.S.; Davis, M.E. Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug. Chem., 2003, 14 (6), 1122-1132.
57. Guo, J.; Ogier, J.R.; Desgranges, S.; Darcy, R.; O'Driscoll, C. Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice. Biomaterials, 2012, 33 (31), 7775-7784.
58. Gonzalez, H.; Hwang, S.J.; Davis, M.E. New class of polymers for the delivery of macromolecular therapeutics. Bioconjug. Chem., 1999, 10 (6), 1068-1074.
59. Hwang, S.J.; Bellocq, N.C.; Davis, M.E. Effects of structure of - cyclodextrin-containing polymers on gene delivery. Bioconjug. Chem., 2001, 12 (2), 280-290.
60. Mishra, S.; Heidel, J.D.; Webster, P.; Davis, M.E. Imidazole groups on a linear, cyclodextrin-containing polycation produce enhanced gene delivery via multiple processes. J. Control. Release, 2006, 116 (2), 179-191.
61. Popielarski, S.R.; Mishra, S.; Davis, M.E. Structural effects of carbohydrate-containing polycations on gene delivery. 3. Cyclodextrin type and functionalization. Bioconjug. Chem., 2003, 14 (3), 672-678.
62. Pun, S.H.; Davis, M.E. Development of a nonviral gene delivery vehicle for systemic application. Bioconjug. Chem., 2002, 13 (3), 630-639.
63. Reineke, T.M.; Davis, M.E. Structural effects of carbohydrate-containing polycations on gene delivery. 2. Charge center type. Bioconjug. Chem., 2003, 14 (1), 255-261.
64. Reineke, T.M.; Davis, M.E. Structural effects of carbohydrate-containing polycations on gene delivery. 1. Carbohydrate size and its distance from charge centers. Bioconjug. Chem., 2003, 14 (1), 247-254.
65. Pun, S.H.; Tack, F.; Bellocq, N.C.; Cheng, J.; Grubbs, B.H.; Jensen, G.S.; Davis, M.E.; Brewster, M.; Janicot, M.; Janssens, B.; Floren, W.; Bakker, A. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol. Ther., 2004, 3 (7), 641-650.
66. Bartlett, D.W.; Davis, M.E. Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol. Bioeng., 2008, 99 (4), 975-985.
67. Bartlett, D.W.; Davis, M.E. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug. Chem., 2007, 18 (2), 456-468.
68. Davis, M.E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: From concept to clinic. Mol. Pharm., 2009, 6 (3), 659-668.
69. Heidel, J.D.; Yu, Z.; Liu, J.Y.C.; Rele, S.M.; Liang, Y.; Zeidan, R.K.; Kornbrust, D.J.; Davis, M.E. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. U. S. A., 2007, 104 (14), 5715-5721.
70. Davis, M.E.; Zuckerman, J.E.; Choi, C.H.J.; Seligson, D.; Tolcher, A.; Alabi, C.A.; Yen, Y.; Heidel, J.D.; Ribas, A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature, 2010, 464 (7291), 1067-1070.
71. Arima, H.; Motoyama, K. Recent findings concerning PAMAM dendrimer conjugates with cyclodextrins as carriers of DNA and RNA. Sensors, 2009, 9 (8), 6346-6361.
72. Arima, H.; Motoyama, K.; Higashi, T. Potential use of polyamidoamine dendrimer conjugates with cyclodextrins as novel carriers for siRNA. Pharmaceuticals, 2012, 5 (1), 61-78.
73. Arima, H.; Motoyama, K.; Higashi, T. Polyamidoamine dendrimer conjugates with cyclodextrins as novel carriers for DNA, shRNA and siRNA. Pharmaceutics, 2012, 4 (1), 130-148.
74. Niederhafner, P.; Sebestik, J.; Jezek, J. Peptide dendrimers. J. Pep. Sci., 2005, 11 (12), 757-788.
75. Niederhafner, P.; Sebestik, J.; Jezek, J. Glycopeptide dendrimers. Part II. J. Pep. Sci., 2008, 14 (1), 44-65.
76. Niederhafner, P.; Sebestik, J.; Jezek, J. Glycopeptide dendrimers. Part I. J. Pep. Sci., 2008, 14 (1), 2-43.
77. Ortiz, M.C.; Garcia, J.M.; Benito, J.M. Cyclodextrin-based gene delivery systems. Chem. Soc. Rev., 2011, 40 (3), 1586-1608.
78. Pack, D.W.; Hoffman, A.S.; Pun, S.; Stayton, P.S. Design and development of polymers for gene delivery. Nat. Rev. Drug Discov., 2005, 4 (7), 581-593.
79. Tros de, I.C.; Sun, Y.; Duzgunes, N. Gene delivery by lipoplexes and polyplexes. Eur. J. Pharm. Sci., 2010, 40 (3), 159-170.
80. Arima, H.; Kihara, F.; Hirayama, F.; Uekama, K. Enhancement of gene expression by polyamidoamine dendrimer conjugates with -α, β, and γ cyclodextrins. Bioconjug. Chem., 2001, 12 (4), 476-484.
81. Ohtani, Y.; Irie, T.; Uekama, K.; Fukunaga, K.; Pitha, J. Differential effects of α, β, and γ cyclodextrins on human erythrocytes. Eur. J. Biochem., 1989, 186 (1-2), 17-22.
82. Kihara, F.; Arima, H.; Tsutsumi, T.; Hirayama, F.; Uekama, K. In vitro and in vivo gene transfer by an optimized -cyclodextrin conjugate with polyamidoamine dendrimer. Bioconjug. Chem., 2003, 14 (2), 342-350.
83. Kihara, F.; Arima, H.; Tsutsumi, T.; Hirayama, F.; Uekama, K. Effects of structure of polyamidoamine dendrimer on gene transfer efficiency of the dendrimer conjugate with -cyclodextrin. Bioconjug. Chem., 2002, 13 (6), 1211-1219.
84. Tsutsumi, T.; Hirayama, F.; Uekama, K.; Arima, H. Evaluation of polyamidoamine dendrimer/ -cyclodextrin conjugate (generation 3, G3) as a novel carrier for small interfering RNA (siRNA). J. Control. Release, 2007, 119 (3), 349-359.
85. Tsutsumi, T.; Hirayama, F.; Uekama, K.; Arima, H. Potential use of polyamidoamine dendrimer/ -cyclodextrin conjugate (generation 3, G3) as a novel carrier for short hairpin RNA-expressing plasmid DNA. J. Pharm. Sci., 2008, 97 (8), 3022-3034.
86. Arima, H.; Tsutsumi, T.; Yoshimatsu, A.; Ikeda, H.; Motoyama, K.; Higashi, T.; Hirayama, F.; Uekama, K. Inhibitory effect of siRNA complexes with polyamidoamine dendrimer/ -cyclodextrin conjugate (generation 3, G3) on endogenous gene expression. Eur. J. Pharm. Sci., 2011, 44 (3), 375-384.
87. Anno, T.; Higashi, T.; Motoyama, K.; Hirayama, F.; Uekama, K.; Arima, H. Possible enhancing mechanisms for gene transfer activity of glucuronylglucosyl-cyclodextrin/dendrimer conjugate. Int. J. Pharm., 2012, 426 (1-2), 239-247.
88. Anno, T.; Higashi, T.; Motoyama, K.; Hirayama, F.; Uekama, K.; Arima, H. Potential use of glucuronylglucosyl-cyclodextrin/dendrimer conjugate (G2) as a DNA carrier in vitro and in vivo. J. Drug Target., 2012, 20 (3), 272-280.
89. Anno, T.; Motoyama, K.; Higashi, T.; Hirayama, F.; Uekama, K.; Arima, H. Preparation and evaluation of polyamidoamine dendrimer (G2)/branched-cyclodextrin conjugate as a novel gene transfer carrier. J. Incl. Phenom. Macrocycl. Chem., 2011, 70 (3/4), 339-344.
90. Van, T.V.F.; Van Broeckhoven, C.; Berneman, Z.N. Gene therapy: principles and applications to hematopoietic cells. Leukemia, 2001, 15 (4), 523-544.
91. Gazi, U.; Martinez-Pomares, L. Influence of the mannose receptor in host immune responses. Immunobiology, 2009, 214 (7), 554-561.
92. Arima, H.; Chihara, Y.; Arizono, M.; Yamashita, S.; Wada, K.; Hirayama, F.; Uekama, K. Enhancement of gene transfer activity mediated by mannosylated dendrimer/ -cyclodextrin conjugate (generation 3, G3). J. Control. Release, 2006, 116 (1), 64-74.
93. Wada, K.; Arima, H.; Tsutsumi, T.; Chihara, Y.; Hattori, K.; Hirayama, F.; Uekama, K. Improvement of gene delivery mediated by mannosylated dendrimer/ -cyclodextrin conjugates. J. Control. Release, 2005, 104 (2), 397-413.
94. Higuchi, Y.; Kawakami, S.; Yamashita, F.; Hashida, M. The potential role of fucosylated cationic liposome/NFkB decoy complexes in the treatment of cytokine-related liver disease. Biomaterials, 2007, 28 (3), 532-539.
95. Rettinger, S.D.; Kennedy, S.C.; Wu, X.; Saylors, R L.; Hafenrichter, D.G.; Flye, M.W.; Ponder, K.P. Liver-directed gene therapy: quantitative evaluation of promoter elements by using in vivo retroviral transduction. Proc. Natl. Acad. Sci. U. S. A., 1994, 91 (4), 1460-1464.
96. Wada, K.; Arima, H.; Tsutsumi, T.; Hirayama, F.; Uekama, K. Enhancing effects of galactosylated dendrimer/ -cyclodextrin conjugates on gene transfer efficiency. Biol. Pharm. Bull., 2005, 28 (3), 500-505.
97. Arima, H.; Yamashita, S.; Mori, Y.; Hayashi, Y.; Motoyama, K.; Hattori, K.; Takeuchi, T.; Jono, H.; Ando, Y.; Hirayama, F.; Uekama, K. In vitro and in vivo gene delivery mediated by lactosylated dendrimer/ -cyclodextrin conjugates (G2) into hepatocytes. J. Control. Release, 2010, 146 (1), 106-117.
98. Motoyama, K.; Mori, Y.; Yamashita, S.; Hayashi, Y.; Jono, H.; Ando, Y.; Hirayama, F.; Uekama, K.; Arima, H. In vitro gene delivery mediated by lactosylated dendrimer (generation 3, G3)/cyclodextrin conjugates into hepatocytes. J. Incl. Phenom. Macrocycl. Chem., 2011, 70 (3/4), 333-338.
99. Hayashi, Y.; Mori, Y.; Higashi, T.; Motoyama, K.; Jono, H.; Sah, D.W.Y.; Ando, Y.; Arima, H. Systemic delivery of transthyretin siRNA mediated by lactosylated dendrimer/ -cyclodextrin conjugates into hepatocyte for familial amyloidotic polyneuropathy therapy. Amyloid, 2012, 19 (SUPPL. 1), 47-49.
100. Hayashi, Y.; Mori, Y.; Yamashita, S.; Motoyama, K.; Higashi, T.; Jono, H.; Ando, Y.; Arima, H. Potential use of lactosylated dendrimer (G3)/ -cyclodextrin conjugates as hepatocyte-specific siRNA carriers for the treatment of familial amyloidotic polyneuropathy. Mol. Pharm., 2012, 9 (6), 1645-1653.
101. Hayashi, Y.; Higashi, T.; Motoyama, K.; Mori, Y.; Jono, H.; Ando, Y.; Arima, H. Design and evaluation of polyamidoamine dendrimer conjugate with PEG, a-cyclodextrin and lactose as a novel hepatocyte-selective gene carrier in vitro and in vivo. J. Drug Target., 2013, 21 (5), 487-496.
102. Harata, M.; Soda, Y.; Tani, K.; Ooi, J.; Takizawa, T.; Chen, M.; Bai, Y.; Izawa, K.; Kobayashi, S.; Tomonari, A.; Nagamura, F.; Takahashi, S.; Uchimaru, K.; Iseki, T.; Tsuji, T.; Takahashi, T.A.; Sugita, K.; Nakazawa, S.; Tojo, A.; Maruyama, K.; Asano, S. CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. Blood, 2004, 104 (5), 1442-1449.
103. Roche, A.C.; Fajac, I.; Grosse, S.; Frison, N.; Rondanino, C.; Mayer, R.; Monsigny, M. Glycofection: Facilitated gene transfer by cationic glycopolymers. Cell. Mol. Life Sci., 2003, 60 (2), 288-297.
104. Chen, H.; Ahn, R.; Van Den Bossche, J.; Thompson, D.H.; O'Halloran, T.V. Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Mol. Cancer Ther., 2009, 8 (7), 1955-1963.
105. Lu, Y.; Low, P.S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Del. Rev., 2002, 54 (5), 675-693.
106. Hatakeyama, H.; Akita, H.; Maruyama, K.; Suhara, T.; Harashima, H. Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. Int. J. Pharm., 2004, 281 (1/2), 25-33.
107. Miyajima, Y.; Nakamura, H.; Kuwata, Y.; Lee, J.D.; Masunaga, S.; Ono, K.; Maruyama, K. Transferrin-loaded nido-carborane liposomes: Tumor-targeting boron delivery system for neutron capture therapy. Bioconjug. Chem., 2006, 17 (5), 1314-1320.
108. Kim, I.Y.; Kang, Y.S.; Lee, D.S.; Park, H.J.; Choi, E.K.; Oh, Y.K.; Son, H.J.; Kim, J.S. Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice. J. Control. Release, 2009, 140 (1), 55-60.
109. Schiffelers, R.M.; Koning, G.A.; Ten Hagen, T.L.M.; Fens, M.H.A.M.; Schraa, A.J.; Janssen, A.P.C. A.; Kok, R.J.; Molema, G.; Storm, G. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J. Control. Release, 2003, 91 (1/2), 115-122.
110. Leamon, C.P.; Low, P.S. Folate-mediated targeting: From diagnostics to drug and gene delivery. Drug Discov. Today, 2001, 6 (1), 44-51.
111. Parker, N.; Turk, M.J.; Westrick, E.; Lewis, J.D.; Low, P.S.; Leamon, C.P. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal. Biochem., 2005, 338 (2), 284-293.
112. Arima, H.; Arizono, M.; Higashi, T.; Yoshimatsu, A.; Ikeda, H.; Motoyama, K.; Hattori, K.; Takeuchi, T.; Hirayama, F.; Uekama, K. Potential use of folate-polyethylene glycol (PEG)-appended dendrimer (G3) conjugate with -cyclodextrin as DNA carriers to tumor cells. Cancer Gene Ther., 2012, 19 (5), 358-366.
113. Arima, H.; Yoshimatsu, A.; Ikeda, H.; Ohyama, A.; Motoyama, K.; Higashi, T.; Tsuchiya, A.; Niidome, T.; Katayama, Y.; Hattori, K.; Takeuchi, T. Folate-PEG-appended dendrimer conjugate with -cyclodextrin as a novel cancer cell-selective siRNA delivery carrier. Mol. Pharm., 2012, 9 (9), 2591-2604.
114. Harada, A. Construction of supramolecular structures from cyclodextrins and polymers. Carbohydr. Polym., 1997, 34 (3), 183-188.
115. Higashi, T.; Hirayama, F.; Misumi, S.; Arima, H.; Uekama, K. Design and evaluation of polypseudorotaxanes of pegylated insulin with cyclodextrins as sustained release system. Biomaterials, 2008, 29 (28), 3866-3871.
116. Motoyama, K.; Hayashida, K.; Arima, H. Potential use of polypseudorotaxanes of pegylated polyamidoamine dendrimer with cyclodextrins as novel sustained release systems for DNA. Chem. Pharm. Bull., 2011, 59 (4), 476-479.
117. Motoyama, K.; Hayashida, K.; Higashi, T.; Arima, H. Polypseudorotaxanes of pegylated -cyclodextrin/polyamidoamine dendrimer conjugate with cyclodextrins as a sustained release system for DNA. Bioorg. Med. Chem., 2012, 20 (4), 1425-1433.